Literature DB >> 19194690

[Botulinum toxin in nonneurogenic bladder dysfunction].

U Mehnert1, B Schurch.   

Abstract

Nonneurogenic overactive bladder with or without detrusor overactivity and/or incontinence is a bothersome symptom for many people. Until a few years ago, it could be treated only with anticholinergic drugs or invasive surgery. Intradetrusor injection with botulinum toxin type A is a minimally invasive alternative therapy option for patients who do not respond to or tolerate anticholinergic treatment. This literature overview summarises the relevant articles on this topic over the last 6 years and provides information on the efficacy, adverse events, currently used dosages, and injection techniques. Overall, a favourable initial efficacy has been observed starting around day 4 after injection and can last up to approximately 31 weeks. Depending on the dose, however, elevated postvoid residual volumes should be anticipated and might require clean intermittent self-catheterisation. The use of botulinum toxin in the urinary bladder is still considered off-label.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19194690     DOI: 10.1007/s00120-008-1918-8

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  38 in total

1.  Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.

Authors:  D M Schmid; P Sauermann; M Werner; B Schuessler; N Blick; M Muentener; R T Strebel; D Perucchini; D Scheiner; G Schaer; H John; A Reitz; D Hauri; B Schurch
Journal:  J Urol       Date:  2006-07       Impact factor: 7.450

Review 2.  Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc.

Authors:  D Dressler; M Hallett
Journal:  Eur J Neurol       Date:  2006-02       Impact factor: 6.089

3.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

Authors:  Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams
Journal:  Eur Urol       Date:  2006-10-02       Impact factor: 20.096

4.  Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction.

Authors:  Heinrich Schulte-Baukloh; Catarina Weiss; Thomas Stolze; Jaqueline Herholz; Burkard Stürzebecher; Kurt Miller; Helmut H Knispel
Journal:  Eur Urol       Date:  2005-07-18       Impact factor: 20.096

5.  Is the bladder a reliable witness for predicting detrusor overactivity?

Authors:  H Hashim; P Abrams
Journal:  J Urol       Date:  2006-01       Impact factor: 7.450

6.  Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux.

Authors:  Gilles Karsenty; Ehab Elzayat; Thomas Delapparent; Benoît St-Denis; Marie-Claude Lemieux; Jacques Corcos
Journal:  J Urol       Date:  2007-03       Impact factor: 7.450

Review 7.  Questionnaires to assess urinary and anal incontinence: review and recommendations.

Authors:  K N L Avery; J L H R Bosch; M Gotoh; M Naughton; S Jackson; S C Radley; L Valiquette; J Batista; J L Donovan
Journal:  J Urol       Date:  2007-01       Impact factor: 7.450

8.  Treatment of overactive bladder with botulinum toxin type B: a pilot study.

Authors:  Dennis Dykstra; Al Enriquez; Michael Valley
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2003-11-25

9.  Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity.

Authors:  Stephen Jeffery; Michelle Fynes; Frank Lee; Kate Wang; Lin Williams; Roland Morley
Journal:  BJU Int       Date:  2007-12       Impact factor: 5.588

10.  Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity.

Authors:  Vinay Kalsi; Apostolos Apostolidis; Gwen Gonzales; Sohier Elneil; Prokar Dasgupta; Clare J Fowler
Journal:  Eur Urol       Date:  2007-12-26       Impact factor: 20.096

View more
  2 in total

1.  [Effects of botulinum toxin type A in the single and repeated treatment of overactive bladder. A prospective analysis].

Authors:  C Frohme; Z Varga; P Olbert; A J Schrader; R Hofmann; A Hegele
Journal:  Urologe A       Date:  2010-05       Impact factor: 0.639

2.  [Value of nerve growth factor levels in overactive bladder syndrome: alterations after botulinum toxin therapy].

Authors:  S Knippschild; C Frohme; P Olbert; R Hofmann; A Hegele
Journal:  Urologe A       Date:  2012-03       Impact factor: 0.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.